TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.31
+5.26%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 338.09x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.62x
- Price / sales
- 255.74x
- Price / cash flow
- -10.61x
Enterprise value
- Enterprise value
- $1.0B
- EV / sales
- 182.84x
- EV / EBITDA
- -6.74x
- EV / EBIT
- -6.55x
- Market cap
- $1.4B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026